Why America is copying healthcare systems from ‘middle-income’ African countries

Value-based pricing has become an important topic of discussion in healthcare in the United States. Although value-based pricing is intended to regulate prices of drugs based on their actual value, prices for a single drug can still vary significantly.

Authors Anna Kaltenboeck, MA, and Peter B. Bach, MD, both of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center, suggested that value-based pricing has refined itself and now can initiate any change to traditional payment models for drugs, which does not necessarily consider the final price of the product.

“The current system, in which prices reflect 'what the market will bear,' has been plagued by price hikes on legacy drugs and wide dissociations between prices of drugs and their benefits,” the authors of an article, published by JAMA, stated. “The cost of a year of life gained with cancer treatment has been increasing annually by $8500 as a result of accelerating prices for new oncology drugs.”

There is an indication-specific pricing approach that suggests the same drug can have higher and lower prices when the benefits in its indications differ substantially. This specific approach has previously been implemented by both Express Scripts and CVS Caremark for cancer drugs, while Novartis has announced that its drug tisagenlecleucel (Kymriah) will have indication-specific prices.

“Importantly, the approach is not stand-alone, it is a subpart of value-based pricing, in which a drug’s price is linked to its benefits,” the authors explained. “If prices are not anchored to an external reference, such as a standardized cost per [quality-adjusted life-year] multiplier per indication, indication-specific pricing could allow pharmaceutical corporations to charge even higher net prices for their products.”


READ MORE

https://www.ajmc.com/newsroom/valuebased-pricing-is-in-place-but-prices-for-a-single-drug-vary

Recent Posts

See All

Hi from HIMSS19!

By Albert DiPiero MD MPH I am at the annual HIMSS meeting in Orlando Florida this week. HIMSS is the Healthcare Information and Management Systems Society. A few quick thoughts: The sheer volume of he

CVS explores new concepts in healthcare

By Albert DiPiero MD MPH CVS - the drug store chain which is also one of America's largest retailers - is not waiting to see what Amazon is up to. CVS is pushing ahead transforming itself from retail

Amazon health venture hires CTO

By Albert DiPiero MD MPH The joint healthcare venture between Amazon-Berkshire Hathaway-JP Morgan Chase (ABJ) just announced the hiring of Serkan Kutan as its CTO. Mr Kutan was most recently chief tec